Dr. Royal

Walter Royal, III, M.D.

Walter Royal, III, M.D.

Dr. Royal is the Director of the Maryland Center for Multiple Sclerosis Treatment and Research and a Professor of Neurology and Professor of Anatomy and Neurobiology at the University Of Maryland School Of Medicine. He is also the Research Associate Director for the VA Multiple Sclerosis Center of Excellence-East. Dr. Royal is an active investigator in the Maryland Center for MS clinical trials program and also has a laboratory which is researching immune markers of MS disease progression and mechanisms by which the activity of nuclear receptors, specifically the vitamin A and vitamin D receptors, modulate proinflammatory immune responses in MS. His research also involves studies of the viral pathogenesis of MS as well as clinical and basic science studies of the epidemiology and pathogenesis of neurocognitive impairment that occurs among individuals with human immunodeficiency virus type-1 (HIV-1) infection. His HIV-related research involves collaborations with investigators at the University of Maryland Institute for Human Virology (IHV), in Abuja, Nigeria and at the University of California, San Diego and studies of a HIV-1 transgenic rat model, also in collaboration with researchers at the IHV.

Dr. Royal will see patients in the Neurology Ambulatory Center on Tuesdays. Appointments may be made by calling the appointment desk at 410-328-4323.

Administrative Office Address:

Patient Appointment Address:
Maryland Center for MS
110 South Paca St., 3rd floor
Baltimore, MD 21201
Phone 410-328-5605
Fax 410-328-5425
Neurology Ambulatory Center
16 South Eutaw Street, 3rd floor
Baltimore, MD 21201
Phone 410-328-5858
Fax 410-328-1149

Education and Training:
1973-1977


Harvard College
Cambridge, Massachusetts
A.B., Biochemistry
1977-1980

Dartmouth Medical School     M.D.
Hanover, New Hampshire
1980-1983

Residency in Internal Medicine
Faulkner Hospital, Boston, Massachusetts
1983-1985


Post-doctoral Fellowship
Neurovirology and neuroimmunology
Johns Hopkins University, Baltimore, MD
1985-1988

Residency in Neurology
The Johns Hopkins Hospital, Baltimore, MD
Previous Appointments
1988-1991

Instructor in Neurology
Johns Hopkins University
1991-2000

Assistant Professor in Neurology
Johns Hopkins University
 
Certifications
American Board of Internal Medicine (Certified 9/83)
American Board of Psychiatry and Neurology (Certified 9/90
 
Current Appointments
2011-present

Professor of Neurology
University of MD School of Medicine
2005-2011

Associate Professor of Neurology
University of MD School of Medicine
2000-2005

Associate Professor of Medicine (Neurology and Anatomy and Neurobiology
Morehouse School of Medicine

Selected publications and invited reviews (out of more than 40 published papers)

  • Royal III W. HIV-1 Related Neurologic Disease: Therapeutic Issues. Journal of NeuroVirology 2000; Suppl: S33-S37.

  • Geschwind MD, Slolasky RL, Royal III W, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy. Journal of NeuroVirology. 2001; 7:353-357.

  • Bilak MM, Coarse AM, Royal W , Becerra P, Cristofalo V, Francis MK, Kuncl RW. Pigment epithelium-derived factor (PEDF) is elevated in cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS). J Neurochem 2002; 81:178-184.

  • Royal III W , Khalsa JH, Francis H. Proceedings of a workshop on metabolic disorders in the pathogenesis of nervous system damage in HIV-infected drug users. JAIDS. 2002; 31:S27-S28.

  • Royal III W , Gartner S, Gadjewski CD. Retinol measurements and retinol receptor gene expression in patients with multiple sclerosis. Multiple Sclerosis. 2002; 8:452-458.

  • Royal III W, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T, Post MJ, Fish D, Pailloux G, Poncelet H, Concha M, Apuzzo L, Singer, E. Topotecan in the treatment of AIDS-related progressive multifocal leukoencephalopathy. Journal of NeuroVirology. 2003;9: 411-419.

  • Royal III W, Vlahov D, Lyles C, Gajewski CD. Retinoids and drugs of abuse: Implication for Neurologic Disease Risk in HIV-1 Infection. Clinical Infectious Diseases. 2003; Suppl 5: S427-S432.

  • Retinoid-induced Immunomodulation: inhibition by morphine and implications for nervous system disease in HIV-1 infection. Proceedings from the NIDA-Sponsored Satellite Sessions in Association with the XIV International AIDS Conference, Barcelona, Spain (Satillite Sessions, XIV International AIDS Conference, Barcelona, Spain, July, 2002.) Bethesda, MD, National Institute on Drug Abuse, pp 56-59, 2003.

  • Mou L, Lankford-Turner P, Leander MV, Bissonnette RP, Donohoe RM, Royal W III . RXR-induced TNF-a Suppression is Reversed by Morphine in Phytohemagglutanin-activated U937 Cells. Journal of Neuroimmunology. 2004;147:99-105.

  • Khalsa JH and Royal III W . Do Drugs of Abuse Impact on HIV Disease? Journal of Neuroimmunology. 2004; 147:6-8.

  • For more information about the Maryland Center for Multiple Sclerosis, please call 410-328-5605.

    This page was last updated: July 17, 2013

             
    Average rating (10)